How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer meetings, with adoption of the test predicated on standardization and the perceived value of the test.

Related Videos

September 2, 2015

Relapsed/Refractory Setting

Dixie-Lee Esseltine, MD and George Mulligan, PhD discuss the challenges in the current standards of care of patients with multiple myeloma in the relapse setting.

July 29, 2015

The Status of the Standard of Care for Cancer Patients

Dr. Alex Adjei discusses how the standard of care for cancer patients has improved overt he last few years, but there is still a great need for new treatments designed to help a broader range of cancer patients.